PSGL-1 blockade delays relapse to BRAF/MEK inhibition in cutaneous melanoma

Abstract excerpt

Advanced BRAF-mutant cutaneous melanoma can be treated with targeted therapy when immune checkpoint inhibitors (ICIs) fail or are not a feasible option. Nevertheless, most patients do not achieve a durable response, highlighting the critical need for therapeutic partners that enhance the long-term efficacy of targeted therapy. Transcriptomic analysis of a BRAF-mutant melanoma model of acquired resistance identifie...

Topics

Open a Topic to create a Post that cites this publication.

• CD4-Positive T-Lymphocytes
• Immune Checkpoint Inhibitors
• Lymphocytes, Tumor-Infiltrating
• Membrane Glycoproteins
• Mice, Knockout
• Molecular Targeted Therapy
• Neoplasms
• Tumor Microenvironment

Identifiers and source

Literature Corpus work

1e706a1f-6bde-50d4-a471-bc436670f1a4

DOI

10.64898/2026.07.02.736105